Tivic Health Systems Inc Stock Price, News & Analysis

Tivic Health (NASDAQ: TIVC) has conducted briefings with senior leadership at the White House and FDA regarding potential military and defense applications of its product candidates. The meetings, held on April 17th in Washington D.C., focused on two key programs:

1. The TLR5 program, including lead candidate Entolimod™ and second-generation Entolasta™, which targets acute radiation syndrome treatment. This program has previously received significant funding from various U.S. government agencies including BARDA, NASA, and the Department of Defense.

2. The company's non-invasive cervical vagus nerve stimulation (ncVNS) technology, which shows promise in treating PTSD, inflammatory, cardiac, and neurologic disorders. The FDA discussions explored expedited approval pathways for both programs, with positive feedback received regarding potential breakthrough device designations following clinical work completion.

Tivic Health Systems (Nasdaq: TIVC), a diversified therapeutics company, has successfully regained compliance with Nasdaq's minimum bid price listing requirements under Rule 5550(a)(2). As a result, the company's common stock will maintain its listing and continue trading on the Nasdaq Capital Market under the ticker symbol 'TIVC'.

Tivic Health Systems (TIVC) reported its year-end 2024 financial results, marking a transformative period with strategic expansions in biotech. The company secured exclusive license rights to Entolimod™, a late-stage TLR5 agonist for treating acute radiation syndrome, and progressed in developing non-invasive cervical vagus nerve stimulation (ncVNS) devices.

Key financial metrics for 2024 include:

• Revenue of $0.8M (down from $1.2M in 2023)
• Gross profit decreased to $2,000 (from $287,000 in 2023)
• Operating expenses reduced to $5.7M (from $8.5M in 2023)
• Net loss decreased 30% to $5.7M (from $8.2M in 2023)
• Cash and equivalents at $2.0M (down from $3.4M in 2023)

Notable developments include securing a $25M equity line of credit, executing a 1-for-17 reverse stock split, and expanding their patent portfolio to 27 patents. The company plans to increase R&D investments in vagus nerve platform and advance TLR5 agonist programs.

Tivic Health (Nasdaq: TIVC), a diversified therapeutics company focused on immune and autonomic nervous systems, has scheduled its 2024 year-end financial results announcement for March 21, 2025. The results will be presented through a pre-recorded conference call and webcast at 1:30 PM PT / 4:30 PM ET.

Investors can access the teleconference via toll-free number 1-877-407-0779 (International: 1-201-389-0914) using Conference ID 13752399, or through the webcast link provided.

Tivic Health (Nasdaq: TIVC) has announced new data demonstrating the effectiveness of their personalized non-invasive vagus nerve stimulation (ncVNS) method in optimizing autonomic nervous system activity. The findings were presented at the Sixth Bioelectronic Medicine Summit in collaboration with The Feinstein Institute of Medicine.

Key results from the study showed that:

• No single stimulation frequency had a universal effect, emphasizing the need for personalized approaches
• In 60% of participants, raw Heart Rate Variability (HRV) nearly doubled following ncVNS stimulation
• Normalized HRV increased 2.67x post-stimulation, indicating enhanced parasympathetic activity

The company believes these results support their strategy to develop personalized neuromodulation devices for treating inflammatory, cardiac, and neurologic disorders as alternatives to invasive surgeries and pharmaceuticals.

Tivic Health Systems (Nasdaq: TIVC) has announced a 1-for-17 reverse stock split effective March 7, 2025, at 12:01 AM Eastern Time. The decision comes as part of the Company's Compliance Plan presented to Nasdaq on February 18, 2025, aiming to meet the minimum bid price requirement for continued Nasdaq listing.

The split was approved by stockholders on January 31, 2025, and will automatically convert every 17 shares into one new share. The company will maintain its 'TIVC' trading symbol with a new CUSIP: 888705308. Proportional adjustments will be made to conversion prices, exercise prices, and shares underlying preferred stock, warrants, equity awards, and options.

This action follows a December 2024 Nasdaq delisting notification due to non-compliance with minimum bid price and stockholders' equity requirements. While the Company appealed the determination with a hearing on February 18, 2025, there are no guarantees the reverse split will ensure continued Nasdaq listing.

Tivic Health Systems (Nasdaq: TIVC) has filed Patent No. 63,492,402 with the U.S. Patent Office for a 'Method and Apparatus for Electrical Stimulation of the Vagus Nerve.' The patent aims to protect the company's technology for non-invasive cervical vagus nerve stimulation (VNS) device ahead of potential FDA approval and commercialization.

According to Blake Gurfein, Tivic Health's Chief Scientific Officer, research conducted at the Feinstein Institute demonstrated that personalizing stimulation parameters for each subject leads to significantly improved effects on autonomous nervous system measures compared to one-size-fits-all approaches. This customization capability is expected to enable more effective device therapies and create compelling use cases for targeted indications.

Tivic Health Systems (Nasdaq: TIVC) has appointed Michael K. Handley as President of Tivic Biopharma and Chief Operating Officer. Handley, former CEO of Statera Biopharma, will lead the company's newly formed biopharma division and oversee the development of Entolimod™, a recently licensed late-stage product candidate.

Throughout his career, Handley has contributed to the global commercialization of 17 drugs and devices generating approximately $7 billion in annual sales. His responsibilities will include building the biopharma team, advancing Entolimod through manufacturing validation, regulatory approval, and commercialization.

As part of his employment agreement, Tivic granted Handley 600,000 restricted stock units (RSUs) as an inducement award. The RSUs will vest over four years, with 25% vesting after one year and the remainder vesting in 12 quarterly installments, subject to continuous service.

Tivic Health Systems (NASDAQ: TIVC) has acquired worldwide exclusive license rights from Statera Biopharma for Entolimod™, a late-stage TLR5 agonist targeting acute radiation syndrome (ARS). The agreement includes an exclusive option for five additional indications for Entolimod and its derivative, Entalasta™.

This strategic move transforms Tivic from a single-product, direct-to-consumer company into a diversified therapeutics company. Entolimod has received FDA Fast Track and Orphan Drug designation for ARS treatment and has undergone over forty animal and human trials with $140 million in prior investment.

The global ARS market is valued at $5.2 billion in 2024, with a projected 5% annual growth rate through 2031. The acquisition positions Tivic to address immune and autonomic dysregulation through both neural and molecular pathways, with potential FDA approval within 24 months.